Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Eun Ji Park, Sung Mook Lim, Kang Choon Lee & Dong Hee Na. (2016) Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015). Expert Opinion on Therapeutic Patents 26:7, pages 833-842.
Read now
Read now
Hui Wu, Chunhua Sui, Fangzhen Xia, Hualing Zhai, Huixin Zhang, Hui Xu, Pan Weng & Yingli Lu. (2016) Effects of exenatide therapy on insulin resistance in the skeletal muscles of high-fat diet and low-dose streptozotocin-induced diabetic rats. Endocrine Research 41:1, pages 1-7.
Read now
Read now
Amedeo Lonardo, Stefano Ballestri, Giovanni Targher & Paola Loria. (2015) Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 9:5, pages 629-650.
Read now
Read now
Laura Cascales. (2012) New treatments for type 2 diabetes. Medical Writing 21:4, pages 279-283.
Read now
Read now
Thomas D Aicher, Steven A Boyd, Maralee McVean & Anthony Celeste. (2010) Novel therapeutics and targets for the treatment of diabetes. Expert Review of Clinical Pharmacology 3:2, pages 209-229.
Read now
Read now
Articles from other publishers (27)
Namra V Gohil, Nida Tanveer, Vijaya Krishna Makkena, Arturo P Jaramillo, Babatope L Awosusi, Javaria Ayyub, Karan Nareshbhai Dabhi & Tuheen Sankar Nath. (2023) Non-alcoholic Fatty Liver Disease and Its Association With Left Ventricular Diastolic Dysfunction: A Systematic Review. Cureus.
Crossref
Crossref
Heejun Park, Eun‐Sol Ha, Jeong‐Soo Kim & Min‐Soo Kim. (2023) Injectable sustained‐release poly(lactic‐co‐glycolic acid) (PLGA) microspheres of exenatide prepared by supercritical fluid extraction of emulsion process based on a design of experiment approach. Bioengineering & Translational Medicine 8:3.
Crossref
Crossref
Yanli Zhang, Menglin Yang, Xiaohui Wu, Fei Deng, Xu Yin, Rujiang Ma & Linqi Shi. (2022) Glucose-Responsive Nanochaperones Mediate Exendin-4 Delivery for Enhancing Therapeutic Effects. ACS Applied Materials & Interfaces 14:39, pages 44211-44221.
Crossref
Crossref
Gianfranco DI GIUSEPPE, Gea CICCARELLI, Chiara M. CEFALO, Francesca CINTI, Simona MOFFA, Flavia IMPRONTA, Umberto CAPECE, Alfredo PONTECORVI, Andrea GIACCARI & Teresa MEZZA. (2021) Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences. Minerva Endocrinology 46:3.
Crossref
Crossref
Heba A. Habib, Gehan H. Heeba & Mohamed M.A. Khalifa. (2021) Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats. European Journal of Pharmacology 892, pages 173721.
Crossref
Crossref
Xia Lin, Hua Yang, Lili Su, Ziyi Yang & Xing Tang. (2018) Effect of size on the in vitro / in vivo drug release and degradation of exenatide-loaded PLGA microspheres. Journal of Drug Delivery Science and Technology 45, pages 346-356.
Crossref
Crossref
Puxiu Wang, Xuezhi Zhuo, Wei Chu & Xing Tang. (2017) Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity. International Journal of Pharmaceutics 528:1-2, pages 62-75.
Crossref
Crossref
Puxiu Wang, Qian Wang, Tianyang Ren, Haoyu Gong, Jingxin Gou, Yu Zhang, Cuifang Cai & Xing Tang. (2016) Effects of Pluronic F127-PEG multi-gel-core on the release profile and pharmacodynamics of Exenatide loaded in PLGA microspheres. Colloids and Surfaces B: Biointerfaces 147, pages 360-367.
Crossref
Crossref
Zhixia Li, Yuan Zhang, Xiaochi Quan, Zhirong Yang, Xiantao Zeng, Linong Ji, Feng Sun & Siyan Zhan. (2016) Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLOS ONE 11:5, pages e0154206.
Crossref
Crossref
Wonhwa Lee, Eun Ji Park, Soyoung Kwak, Kang Choon Lee, Dong Hee Na & Jong-Sup Bae. (2016) Trimeric PEG-Conjugated Exendin-4 for the Treatment of Sepsis. Biomacromolecules 17:3, pages 1160-1169.
Crossref
Crossref
Sohee Son, Sung Mook Lim, Su Young Chae, Kwangmeyung Kim, Eun Ji Park, Kang Choon Lee & Dong Hee Na. (2015) Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects. International Journal of Pharmaceutics 495:1, pages 81-86.
Crossref
Crossref
Feng Sun, Shanshan Wu, Shuxia Guo, Kai Yu, Zhirong Yang, Lishi Li, Yuan Zhang, Linong Ji & Siyan Zhan. (2014) Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis. Endocrine 48:3, pages 794-803.
Crossref
Crossref
Feng Sun, Shanshan Wu, Jing Wang, Shuxia Guo, Sanbao Chai, Zhirong Yang, Lishi Li, Yuan Zhang, Linong Ji & Siyan Zhan. (2015) Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clinical Therapeutics 37:1, pages 225-241.e8.
Crossref
Crossref
Julio Rosenstock, Vivian A. Fonseca, Jorge L. Gross, Robert E. Ratner, Bo Ahrén, Francis C.C. Chow, Fred Yang, Diane Miller, Susan L. Johnson, Murray W. Stewart & Lawrence A. Leiter. (2014) Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro. Diabetes Care 37:8, pages 2317-2325.
Crossref
Crossref
S. Wu, F. Sun, Y. Zhang, Z. Yang, T. Hong, Y. Chen & S. Zhan. (2014) The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics 39:1, pages 7-13.
Crossref
Crossref
Alfonso López Ruiz, María Ángeles Núñez Sánchez, Noelia Victoria García-Talavera Espín, Amparo Meoro Avilés, Cristina del Peso Gilsanz, Ricardo Soriano Sánchez, María Teresa Gallego García, José Soriano Palao, María Dolores Ortuño, Sacramento Tomás Navarro & Collaborative Groups of the Diabetes and Obesity Unit of the Hospital Reina Sofía. (2014) Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2. Pharmacology & Pharmacy 05:04, pages 433-443.
Crossref
Crossref
Hui Wu, Chunhua Sui, Hui Xu, Fangzhen Xia, Hualing Zhai, Huixin Zhang, Pan Weng, Bing Han, Sichun Du & Yingli Lu. (2014) The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp. Journal of Diabetes Research 2014, pages 1-10.
Crossref
Crossref
Miguel Camafort-Babkowski. (2013) Impacto del tratamiento antidiabético con fármacos agonistas del receptor de péptido de tipo 1 similar al glucagón en el riesgo cardiovascular de pacientes con diabetes mellitus tipo 2. Medicina Clínica 141:4, pages 167-174.
Crossref
Crossref
Alfonso López Ruiz, María Ángeles Ibáñez Gil, Pedro Pujante Alarcón, Alicia Hernández Torres, Ana Belen Hernández Cascales & María Dolores Hellín Gil. (2013) Evolution of Biochemical Effects of Byetta<sup>®</sup> in Type 2 Diabetics with Cardiovascular Risk. Pharmacology & Pharmacy 04:09, pages 679-683.
Crossref
Crossref
Rupa Ahluwalia & Jiten Vora. (2012) Safety and tolerability of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. The British Journal of Diabetes & Vascular Disease 12:1, pages 6-16.
Crossref
Crossref
Myriam Jean, Mohamad Alameh, Diogo De Jesus, Marc Thibault, Marc Lavertu, Vincent Darras, Monica Nelea, Michael D. Buschmann & Abderrazzak Merzouki. (2012) Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes. European Journal of Pharmaceutical Sciences 45:1-2, pages 138-149.
Crossref
Crossref
Andreja Radman, Matija Gredičak, Ivica Kopriva & Ivanka Jerić. (2011) Predicting Antitumor Activity of Peptides by Consensus of Regression Models Trained on a Small Data Sample. International Journal of Molecular Sciences 12:12, pages 8415-8430.
Crossref
Crossref
Manuel González-OrtizEsperanza Martínez-AbundisJosé A. Robles-CervantesMaria G. Ramos-Zavala. (2011) Effect of Exenatide on Fat Deposition and a Metabolic Profile in Patients with Metabolic Syndrome. Metabolic Syndrome and Related Disorders 9:1, pages 31-34.
Crossref
Crossref
Pablo B. Pedrianes Martín & Pedro L. de Pablos Velasco. (2010) Seguridad y tolerabilidad de los antidiabéticos orales en el tratamiento de la diabetes mellitus tipo 2. Medicina Clínica 135, pages 20-26.
Crossref
Crossref
Wei-Xin Li, Jian-Feng Gou, Jin-Hui Tian, Xiang Yan & Lin Yang. (2010) Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Current Therapeutic Research 71:4, pages 211-238.
Crossref
Crossref
Megan C. Chapter, Caitlin M. White, Angela DeRidder, Wayne Chadwick, Bronwen Martin & Stuart Maudsley. (2010) Chemical modification of Class II G protein-coupled receptor ligands: Frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacology & Therapeutics 125:1, pages 39-54.
Crossref
Crossref
Hyun-Hee Kwak, Won-Sik Shim, Seongmee Hwang, Mi-Kyung Son, Yoon-Ji Kim, Tae-Hyoung Kim, Zee-Hye Yoon, Hyun-Jun Youn, Ghun-Il Lee, Soo-Hyoung Kang & Chang-Koo Shim. (2009) Pharmacokinetics and Efficacy of a Biweekly Dosage Formulation of Exenatide in Zucker Diabetic Fatty (ZDF) Rats. Pharmaceutical Research 26:11, pages 2504-2512.
Crossref
Crossref